CYP450 Inhibition

The most abundant hepatic CYP450 isoform, responsible for metabolizing approximately 50% of all marketed drugs. It features a large, flexible active site capable of accommodating diverse molecular structures.

• Substrates: Midazolam, cyclosporine, simvastatin
• Inhibitors: Ketoconazole, ritonavir, grapefruit juice
• Clinical significance: Co-administration with strong inhibitors can cause up to 10-fold increase in substrate AUC

A highly polymorphic isoform exhibiting significant inter-individual variability. Poor metabolizers represent approximately 7-10% of Caucasians, while ultra-rapid metabolizers carry gene duplications.

• Substrates: Codeine, tamoxifen, fluoxetine
• Inhibitors: Quinidine, paroxetine, bupropion
• Clinical significance: Codeine requires CYP2D6-mediated conversion to morphine for analgesic effect; poor metabolizers derive minimal benefit

The primary isoform responsible for metabolizing warfarin, a narrow therapeutic index anticoagulant. Genetic polymorphisms in CYP2C9 significantly influence dosing requirements and bleeding risk.

• Substrates: S-warfarin, phenytoin, losartan
• Inhibitors: Fluconazole, amiodarone, sulfaphenazole
• Clinical significance: CYP2C9*2 and *3 variants reduce clearance by 30-80%, necessitating genotype-guided warfarin dosing

A clinically significant isoform due to its role in activating clopidogrel, a widely prescribed antiplatelet prodrug. Loss-of-function alleles are prevalent in Asian populations.

• Substrates: Clopidogrel, omeprazole, diazepam
• Inhibitors: Omeprazole, esomeprazole, fluvoxamine
• Clinical significance: ~15% of East Asians carry the CYP2C19*2 loss-of-function allele, associated with reduced clopidogrel activation and increased cardiovascular event risk

An inducible isoform regulated by the aryl hydrocarbon receptor (AhR). Its activity is modulated by environmental factors including smoking and dietary exposures, complicating in silico prediction.

• Substrates: Theophylline, caffeine, clozapine
• Inhibitors: Fluvoxamine, ciprofloxacin, acyclovir
• Clinical significance: Polycyclic aromatic hydrocarbons in cigarette smoke induce CYP1A2, increasing clearance of theophylline by 50-100% in smokers

A highly polymorphic and inducible isoform with substantial inter-individual expression variability, ranging over 100-fold in human liver microsomes. It plays a key role in metabolizing several antiretroviral agents.

• Substrates: Efavirenz, bupropion, methadone
• Inhibitors: Ticlopidine, clopidogrel, voriconazole
• Clinical significance: The CYP2B6*6 allele is associated with elevated efavirenz plasma levels and increased CNS toxicity in HIV patients

A kinetic form of CYP450 inhibition where potency increases after a pre-incubation period with NADPH. This occurs when the parent drug is metabolized into a reactive intermediate that forms a quasi-irreversible complex with the heme iron or apoprotein. TDI is mechanistically distinct from reversible inhibition and is a major cause of clinical drug-drug interactions. Computational models predict TDI liability by analyzing metabolic activation potential and the stability of enzyme-inhibitor adducts.

The computational identification of the specific atomic positions on a drug molecule most susceptible to enzymatic oxidation. Key methodologies include:

• Quantum mechanical calculations of bond dissociation energies and activation barriers
• Machine learning models trained on regioselectivity data from human liver microsome assays
• Docking-based approaches that evaluate the geometric distance between the heme reactive oxygen and each ligand atom Accurate SOM prediction is essential for designing out metabolic liabilities and understanding which metabolites may act as TDI perpetrators.

A rigorous physics-based method, such as FEP+, that computationally mutates one ligand into another to predict the relative change in binding free energy to a CYP450 isoform. Unlike empirical scoring functions, alchemical calculations sample the full thermodynamic ensemble, explicitly accounting for protein flexibility and water network reorganization. These methods achieve near-experimental accuracy for predicting CYP450 inhibition potency changes during lead optimization, though at significant computational cost.

A machine learning paradigm where a single neural network is trained simultaneously on multiple CYP450 isoforms (e.g., 3A4, 2D6, 2C9, 2C19, 1A2). By sharing hidden representations across related tasks, the model learns a generalized molecular embedding that captures features relevant to cytochrome binding. Benefits include:

• Improved performance on isoforms with limited training data
• Implicit regularization that reduces overfitting
• A unified model for rapid isoform selectivity profiling

The process of assigning a confidence interval to CYP450 inhibition predictions, distinguishing between:

• Aleatoric uncertainty: Inherent noise in the experimental data, such as IC50 variability across assay conditions
• Epistemic uncertainty: Model ignorance due to limited training data in certain regions of chemical space Techniques like conformal prediction provide rigorous, finite-sample coverage guarantees, enabling go/no-go decisions with a quantified risk of false negatives in drug safety assessment.

The region of chemical space where a CYP450 inhibition model's predictions are statistically reliable. Defined by the structural and physicochemical similarity of a query compound to the training set. Compounds outside the applicability domain—such as those with novel scaffolds or unusual heterocycles—may yield confident but incorrect predictions. Common domain characterization methods include:

• Mahalanobis distance in descriptor space
• Convex hull analysis of training set coverage
• Nearest neighbor similarity thresholds